WHO: Mental Health Services Disrupted in 93% of Countries

⚠ This alert was published more than 90 days ago.The outbreak situation or advisory level may have changed. Check CDC, WHO, or your government's travel advisories for current information.

Global Mental Health Service Disruption: What Travelers Should Know

The World Health Organization reported (5 October 2020) that the COVID-19 pandemic disrupted or halted critical mental health services in 93% of 130 countries surveyed between June and August 2020, at a time when demand was rising.

Reported disruptions

  • Vulnerable groups: services for children and adolescents (72%), older adults (70%), and women needing antenatal or postnatal support (61%).
  • Talking therapies: counselling and psychotherapy (67%).
  • Substance use care: harm-reduction services (65%); opioid agonist maintenance treatment (45%).
  • Emergency interventions: 35% of countries reported disruptions, including care for prolonged seizures, severe substance withdrawal syndromes, and delirium.
  • Medicine access: 30% reported disruptions to access to medications for mental, neurological and substance use disorders.
  • School and workplace programmes: at least partial disruption in 78% and 75% of countries respectively.

About 70% of countries adopted telemedicine or teletherapy, but uptake was uneven — over 80% of high-income countries versus under 50% of low-income countries. WHO also noted that 89% of countries included mental health and psychosocial support in national COVID-19 response plans, yet only 17% had full additional funding for it.

Context WHO highlighted

Bereavement, isolation, income loss and fear can trigger or worsen mental health conditions; increased alcohol and drug use, insomnia and anxiety were reported. COVID-19 itself has been associated with neurological and mental complications such as delirium, agitation and stroke, and people with pre-existing mental, neurological or substance use disorders may face higher risk of severe outcomes.

Pharmacist's note

From a pharmaceutical-services standpoint, the 30% figure on medicine access is the line that matters most for anyone crossing borders. Supply continuity for chronic central nervous system therapy depends on local stock, local prescribing rules, and — for many psychotropics and opioid agonist therapies — national controlled-substance regulations that differ sharply from those at home. Several agents that are routine prescriptions in one country are restricted or prohibited in another.

Practical, non-clinical planning points: confirm the legal status of each medicine with the destination's embassy or health ministry before departure; carry medicines in original labelled packaging with a copy of the prescription and a clinician's letter; check whether telehealth follow-up is available and lawful where you are travelling; and locate the nearest hospital and crisis line on arrival. Any change to an existing regimen, including dose timing across time zones or substitution of an unavailable product, should be discussed with your own prescriber or pharmacist rather than self-managed.

Source: WHO news release, 5 October 2020. This summary is public information and pharmacist commentary only, not medical advice.

Primary sources

PharmTrip may include promotional content. Products and services are independently evaluated by a licensed pharmacist and rankings are never altered by advertiser requests. Information reflects what was current at the time of writing — please verify the latest terms on each provider's official site.